The N600x Pulse Oximeter is indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate.

The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients who are well or poorly perfused in hospitals, hospital-type facilities, intra-hospital transport, and home environments.

The N-600x with SPD feature is intended for use on adults to detect patterns of desaturation that are indicative of repetitive reductions in airflow through the upper airway and in to the lungs.

Device Description

This section describes the N-600x Pulse Oximeter with SPD. The N-600x with SPD is comprised of the N-600x Pulse Oximeter with SPD software and a variety of OxiMax Adult Sensors and cables that have been previously cleared.

The Saturation Pattern Detection (SPD) is a software option which is compatible with the N-600x. The software option is intended to add an advanced SpO2 trend analysis feature. SPD will detect patterns in the saturation trend that are associated with a reduction in airflow and provide annunciation. The SPD feature mines information that is present in the SpO2 trend history stored in the monitor and alerts the caregiver to patterns in that trend. The SPD feature is a means of evaluating the SpO2 information being collected by the oximeter, analogous to the threshold or SatSeconds™ alarm features currently available on the predicate device. The addition of the SPD feature to the predicate device does not affect the device hardware.

AI/ML Overview

The provided text is a 510(k) summary for the Covidien OxiMax N-600x Pulse Oximeter with Saturation Pattern Detection (SPD). While it details the device description, intended use, technological characteristics, and regulatory approval, it does not include specific acceptance criteria or a detailed study description with performance metrics, sample sizes, ground truth establishment, or multi-reader multi-case study results.

The document states that "Clinical and non-clinical tests were performed to support the determination of substantial equivalence" and that "The technological characteristics... and the results of non-clinical and clinical tests do not raise new questions of safety or effectiveness." However, it does not provide the specifics of these tests.

Therefore,Based on the provided text, I cannot provide the complete information requested in the prompt. The document is a 510(k) summary focused on regulatory clearance based on substantial equivalence, rather than a detailed study report with performance metrics and acceptance criteria.

Here's what can be extracted and what information is missing:

1. Table of Acceptance Criteria and Reported Device Performance:

Acceptance Criteria	Reported Device Performance
Not specified in the provided text.	Not specified in the provided text.

The document mentions that "Clinical and non-clinical tests were performed to support the determination of substantial equivalence" but does not detail what specific performance metrics were measured or the thresholds for acceptance for the SPD feature.

2. Sample Size Used for the Test Set and Data Provenance:

Sample Size (Test Set): Not specified.
Data Provenance: Not specified (e.g., country of origin, retrospective or prospective). The document only states that "Clinical studies were conducted following regulations under Title 21 of the Code of Federal Regulations (21 CFR), Part 812 - Investigational Device Exemptions, Part 50 - Protection of Human Subjects and Part 56 - Institutional Review Boards."

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications:

Number of Experts: Not specified.
Qualifications of Experts: Not specified.

4. Adjudication Method for the Test Set:

Adjudication Method: Not specified.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done:

MRMC Study: Not mentioned or implied for the SPD feature. The SPD feature is described as a "software option which is compatible with the N-600x" and "a means of evaluating the SpO2 information being collected by the oximeter," suggesting it's an automated alert system rather than a tool for human readers to interpret directly in a comparative effectiveness study.
Effect Size of AI vs. Without AI Assistance: Not applicable or not provided.

6. If a Standalone Study (Algorithm Only) was Done:

The description of SPD as "a software option... intended to add an advanced SpO2 trend analysis feature" that "detects patterns in the saturation trend... and provides annunciation" strongly suggests a standalone algorithmic performance study would have been conducted to validate its ability to detect these patterns. However, the details of such a study are not provided in this summary.

7. Type of Ground Truth Used:

The SPD feature is intended "to detect patterns of desaturation indicative of repetitive reductions in airflow through the upper airway and into the lungs." Therefore, the ground truth would likely involve polysomnography (PSG) or other definitive methods for identifying actual repetitive airflow reductions or desaturation events, but this is not explicitly stated in the document.

8. Sample Size for the Training Set:

Sample Size (Training Set): Not specified.

9. How the Ground Truth for the Training Set was Established:

Ground Truth Establishment (Training Set): Not specified.

Summary

{0}------------------------------------------------

510(k) Summary

KO8335

Submitted by:

Covidien, (formerly Nellcor Puritan Bennett Inc.) 6135 Gunbarrel Avenue Boulder, CO 80301

Company Contact:

Scott Dickerhoff Director. Requlatory Affairs Phone: (303) 305-2382 Fax: (303) 305-2212

MAR - 9 2009

November 3, 2008 Date Summary Prepared:

Trade Name: -

OxiMax N-600x Pulse Oximeter with SPD

Pulse Oximeter, Sensors and Cables

Common/Usual Name:

Classification Name:

Oximeter (74DQA) (per 21 CFR §870.2700) Patient Transducer and Electrode Cable (including connector) (74DSA) (per 21 CFR §870.2900)

Substantially Equivalent Devices:

OxiMax Pulse Oximetry System with N-600x Pulse Oximeter, K060576 2. Lifescreen Apnea, K042745

I. Device Description

{1}------------------------------------------------

II. Intended Use

The OxiMax N-600x pulse oximeter is intended for prescription use only with neonatal, pediatric, and adult patients who are well or poorly perfused in hospitals, hospital-type facilities, intra-hospital transport, and home environments. The saturation pattern detection with OXIMAX™ SPD™ technology (SPD) feature is intended only for facility use care of adults to detect patterns of desaturation indicative of repetitive reductions in airflow through the upper airway and into the lungs.

III. Technological Characteristics

The OxiMax Pulse Oximetry System measures functional oxygen saturation noninvasively via a light signal interacting with tissue, by utilizing the time-varying changes in tissue optical properties that occur with pulsatile blood flow. Red and infrared lightemitting diodes (LEDs) are utilized as light sources. A photodiode acting as a photodetector senses the signal strengths of the two wavelengths of light, which vary with the amount of light transmitted through the tissue. The N-600x Pulse Oximeter receives this electrical information from the sensor and processes the information by use of an algorithm to provide real time values of SpO2, pulse rate and pulse amplitude.

IV. Tests Performed to Support Determination of Substantial Equivalence

Clinical and non-clinical tests were performed to support the determination of substantial equivalence. Clinical studies were conducted following regulations under Title 21 of the Code of Federal Regulations (21 CFR), Part 812 - Investigational Device Exemptions, Part 50 - Protection of Human Subjects and Part 56 - Institutional Review Boards.

V. Conclusions

The technological characteristics of the OxiMax N-600x Pulse Oximetry System with SPD and the results of non-clinical and clinical tests do not raise new questions of safety or effectiveness when compared to the legally marketed predicate devices.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized human figure with three arms reaching upwards, representing health, services, and people. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the figure.

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Scott D. Dickerhoff Director, Regulatory Affairs Covidien 6135 Gunbarrel Avenue Boulder, Colorado 80301

9 2009 MAR

Re: K083325

Trade/Device Name: N-600x Pulse Oximeter with Oximax SPD™ Alert Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: II Product Code: DQA Dated: February 20, 2009 Received: February 23, 2009

Dear Mr. Dickerhoff:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

Page 2 - Mr. Dickerhoff

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Judite y. Michan Ond.

Ginette Y. Michaud, M.D. Acting Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

510(k) Number:

Device Name: N-600x Pulse Oximeter with Oximax SPD™ Alert

Indications for Use:

The N600x Pulse Oximeter is indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate.

The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients who THE N-000X Fullse Damecer of Interiod for acilities, intra-hospital transport, and home environments.

The N-600x with SPD feature is intended for use on adults to detect patterns of desaturation that are indicative of repetitive reductions in airflow through the upper airway and in to the lungs.

AND/OR Over-The-Counter Use _________________(Part 21 CFR 801 Subpart D) (21 CFR 801 Prescription Use × Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

. Concurrence of CDRH, Office of Device Evaluation (ODE)

Suon uane

(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices

510(k) Number: 1083365

Page 26 of 1650

Confidential & Proprietary Information

Covidien

Regulation Number and Section

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).